Literature DB >> 29308691

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

Nikoletta Lendvai1,2, Ioanna Tsakos1, Sean M Devlin3, Wendy L Schaffer2,4, Hani Hassoun1,2, Alexander M Lesokhin1,2, Heather Landau2,5, Neha Korde1,2, Sham Mailankody1,2, Eric Smith1,2, David J Chung2,5, Guenther Koehne2,5, Gunjan L Shah2,5, Aeri Alexander1, Minal Patel6, Andrea Ballagi7, Ida Grundberg7, Sergio A Giralt2,5, Ola Landgren1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29308691      PMCID： PMC6162998          DOI： 10.1080/10428194.2017.1403020

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

Review 1.  Management of Carfilzomib-Associated Cardiac Adverse Events.

Authors:  Joseph Mikhael
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-02-04

Review 2.  Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.

Authors:  Michael Wang; Jie Cheng
Journal:  Oncology (Williston Park)       Date:  2013-12       Impact factor: 2.990

3.  Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.

Authors:  E Wilson Grandin; Bonnie Ky; R Frank Cornell; Joseph Carver; Daniel J Lenihan
Journal:  J Card Fail       Date:  2014-11-26       Impact factor: 5.712

4.  Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.

Authors:  Ajai Chari; Daher Hajje
Journal:  BMC Cancer       Date:  2014-12-04       Impact factor: 4.430

5.  A role of heparin-binding epidermal growth factor-like growth factor in cardiac remodeling after myocardial infarction.

Authors:  Nobuyoshi Tanaka; Katsuhiko Masamura; Masahiro Yoshida; Masayuki Kato; Yasuyuki Kawai; Isamu Miyamori
Journal:  Biochem Biophys Res Commun       Date:  2002-09-20       Impact factor: 3.575

6.  'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.

Authors:  Sophia Danhof; Martin Schreder; Leo Rasche; Susanne Strifler; Hermann Einsele; Stefan Knop
Journal:  Eur J Haematol       Date:  2015-09-21       Impact factor: 2.997

7.  Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.

Authors:  A Jordán; V Roldán; M García; J Monmeneu; F G de Burgos; G Y H Lip; F Marín
Journal:  J Intern Med       Date:  2007-09       Impact factor: 8.989

8.  Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.

Authors:  S Atrash; A Tullos; S Panozzo; M Bhutani; F Van Rhee; B Barlogie; S Z Usmani
Journal:  Blood Cancer J       Date:  2015-01-16       Impact factor: 11.037

9.  Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability.

Authors:  Erika Assarsson; Martin Lundberg; Göran Holmquist; Johan Björkesten; Stine Bucht Thorsen; Daniel Ekman; Anna Eriksson; Emma Rennel Dickens; Sandra Ohlsson; Gabriella Edfeldt; Ann-Catrin Andersson; Patrik Lindstedt; Jan Stenvang; Mats Gullberg; Simon Fredriksson
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

10.  Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.

Authors:  Carol Chen-Scarabelli; Giovanni Corsetti; Evasio Pasini; Francesco S Dioguardi; Gagan Sahni; Jagat Narula; Mara Gavazzoni; Hemang Patel; Louis Saravolatz; Richard Knight; Riccardo Raddino; Tiziano M Scarabelli
Journal:  EBioMedicine       Date:  2017-05-23       Impact factor: 8.143
View more
  10 in total

Review 1.  Biomarker Discovery in Cardio-Oncology.

Authors:  Anita Vohra; Aarti Asnani
Journal:  Curr Cardiol Rep       Date:  2018-05-25       Impact factor: 2.931

Review 2.  Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.

Authors:  Monica Epstein; Candis Morrison
Journal:  Semin Oncol       Date:  2022-02-10       Impact factor: 5.385

Review 3.  Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Authors:  Ajai Chari; A Keith Stewart; Stuart D Russell; Philippe Moreau; Joerg Herrmann; Jose Banchs; Roman Hajek; John Groarke; Alexander R Lyon; George N Batty; Sunhee Ro; Mei Huang; Karim S Iskander; Daniel Lenihan
Journal:  Blood Adv       Date:  2018-07-10

4.  Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study.

Authors:  Efstathios Kastritis; Ageliki Laina; Georgios Georgiopoulos; Maria Gavriatopoulou; Eleni-Dimitra Papanagnou; Evangelos Eleutherakis-Papaiakovou; Despina Fotiou; Nikolaos Kanellias; Ioanna Dialoupi; Nikolaos Makris; Efstathios Manios; Magdalini Migkou; Maria Roussou; Maria Kotsopoulou; Konstantinos Stellos; Evangelos Terpos; Ioannis P Trougakos; Kimon Stamatelopoulos; Meletios A Dimopoulos
Journal:  Leukemia       Date:  2021-02-15       Impact factor: 12.883

Review 5.  The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?

Authors:  Dickran Kazandjian; Clifton C Mo; Ola Landgren; Paul G Richardson
Journal:  Br J Haematol       Date:  2020-06-05       Impact factor: 8.615

6.  The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma.

Authors:  Teruhito Takakuwa; Ippei Otomaru; Taku Araki; Akiko Miura; Yotaro Fujitani; Yasuhide Mochizuki; Yoshimi Miyagi; Hideto Senzaki; Ryosuke Yamamura
Journal:  Case Rep Hematol       Date:  2019-04-28

Review 7.  Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.

Authors:  Ola Landgren; Pieter Sonneveld; Andrzej Jakubowiak; Mohamad Mohty; Karim S Iskander; Khalid Mezzi; David S Siegel
Journal:  Leukemia       Date:  2019-07-24       Impact factor: 11.528

Review 8.  Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.

Authors:  David J Sherman; Jing Li
Journal:  Molecules       Date:  2020-02-05       Impact factor: 4.411

9.  Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.

Authors:  Rohit Bishnoi; Zhigang Xie; Chintan Shah; Jiang Bian; Hemant S Murthy; John R Wingard; Nosha Farhadfar
Journal:  Cancer Med       Date:  2020-11-10       Impact factor: 4.452

Review 10.  The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.

Authors:  Taylor Harding; Linda Baughn; Shaji Kumar; Brian Van Ness
Journal:  Leukemia       Date:  2019-01-25       Impact factor: 11.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.